Morgan Stanley’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,449,140
| Closed | -$340M | – | 8584 |
|
|
2026
Q1 | $340M | Sell |
6,449,140
-1,496,468
| -19% | -$61.5M | 0.02% | 692 |
|
|
2025
Q4 | $321M | Buy |
7,945,608
+356,513
| +5% | +$8.24M | 0.02% | 709 |
|
|
2025
Q3 | $57M | Buy |
7,589,095
+335,626
| +5% | +$2.14M | ﹤0.01% | 1901 |
|
|
2025
Q2 | $27.1M | Buy |
7,253,469
+143,364
| +2% | +$448K | ﹤0.01% | 2509 |
|
|
2025
Q1 | $19.6M | Buy |
7,110,105
+3,762,298
| +112% | +$15.4M | ﹤0.01% | 2713 |
|
|
2024
Q4 | $18.5M | Buy |
3,347,807
+2,564,875
| +328% | +$17.4M | ﹤0.01% | 2823 |
|
|
2024
Q3 | $6.53M | Buy |
782,932
+449,314
| +135% | +$3.7M | ﹤0.01% | 3750 |
|
|
2024
Q2 | $2.27M | Sell |
333,618
-253,175
| -43% | -$1.53M | ﹤0.01% | 4479 |
|
|
2024
Q1 | $3.85M | Sell |
586,793
-1,137,913
| -66% | -$7.43M | ﹤0.01% | 4121 |
|
|
2023
Q4 | $11.2M | Buy |
1,724,706
+726,946
| +73% | +$3.84M | ﹤0.01% | 3231 |
|
|
2023
Q3 | $5.02M | Buy |
997,760
+858,170
| +615% | +$5.45M | ﹤0.01% | 3736 |
|
|
2023
Q2 | $1.22M | Sell |
139,590
-2,346
| -2% | -$27.3K | ﹤0.01% | 4716 |
|
|
2023
Q1 | $1.68M | Buy |
141,936
+123,878
| +686% | +$1.18M | ﹤0.01% | 4563 |
|
|
2022
Q4 | $184K | Buy |
18,058
+10,815
| +149% | +$72K | ﹤0.01% | 5699 |
|
|
2022
Q3 | $42K | Sell |
7,243
-11,428
| -61% | -$42.5K | ﹤0.01% | 6483 |
|
|
2022
Q2 | $46K | Buy |
18,671
+10,180
| +120% | +$20.3K | ﹤0.01% | 6652 |
|
|
2022
Q1 | $25K | Sell |
8,491
-80,965
| -91% | -$346K | ﹤0.01% | 7049 |
|
|
2021
Q4 | $632K | Buy |
89,456
+63,412
| +243% | +$528K | ﹤0.01% | 5402 |
|
|
2021
Q3 | $271K | Sell |
26,044
-787
| -3% | -$8.16K | ﹤0.01% | 5838 |
|
|
2021
Q2 | $329K | Buy |
+26,831
| New | +$457K | ﹤0.01% | 5757 |
|
Other funds holding TERN
Morgan Stanley's TERN Position: Q2 2026 in Review
Morgan Stanley sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 6,449,140 shares — an estimated $340M sold.
Morgan Stanley first reported a position in TERN in Q2 2021 and held it in 20 quarters. The position peaked at $340M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Morgan Stanley reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Morgan Stanley sold 6,449,140 Terns Pharmaceuticals shares in Q2 2026, an estimated $340M.
- Morgan Stanley first reported a position in Terns Pharmaceuticals in Q2 2021 and held it in 20 quarters.
- Morgan Stanley's Terns Pharmaceuticals position peaked at $340M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.